Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Fischer, Thomas

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Oct 2010 - 4339-45 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1527-7755

10.1200/JCO.2010.28.9678 doi


Administration, Oral
Aged
Antineoplastic Agents--administration & dosage
Female
Humans
Leukemia, Myeloid, Acute--drug therapy
Male
Mutation
Myelodysplastic Syndromes--drug therapy
Receptor Protein-Tyrosine Kinases--genetics
Staurosporine--administration & dosage
Treatment Outcome
fms-Like Tyrosine Kinase 3--genetics